Ochi Y, Kajita Y, Inui T, Yamashiro K, Takasu N, Sato Y, Nagata A
Research Institute for Production Development, Shimogamo, Kyoto, Japan.
Thyroid. 2000 Aug;10(8):653-7. doi: 10.1089/10507250050137725.
Previously we reported that the amounts of cyclic adenosine monophosphate (cAMP) production by polyethylene glycol (PEG) 22.5% precipitated fraction (PF) (crude immunoglobulin G [IgG]) from thyroid-stimulating antibody (TSAb)-positive serum were higher than those by PEG 12.5% PF, and that PEG (5%) augmented affinity purified TSAb-IgG-stimulated cAMP production in porcine thyroid cells (PTC) assay. In the present work, we studied sensitive TSAb assay using whole sera in the presence of high PEG concentrations in PTC assay. cAMP produced by TSAb-positive serum increased in proportion to serum amounts up to 0.05 mL, but gradually decreased in 0.075 mL. The maximal augmentative effect of PEG on TSAb-positive serum (0.05 mL)-stimulated cAMP production was found in 5% PEG (final). Thus, TSAb assay using whole serum (0.05 mL) in the absence of 5% PEG (serum method) and sensitive TSAb (sTSAb) assay using whole serum (0.05 mL) in the presence of 5% PEG (serum plus 5% PEG method) were performed. The sensitive thyroid-stimulating antibody (sTSAb) activities of Graves' sera showed significantly higher (twofold to sevenfold) compared to simple TSAb activity with sera. sTSAb and TSAb activities were positive in 91% (29/32) and 47% (15/32) of untreated Graves' patients with hyperthyroidism. The sTSAb activities by serum plus 5% PEG method were higher than that by PEG 12.5% precipitated fraction (PF) from test serum (0.2 mL) in many Graves' sera, but lower than that by PEG 22.5% PF from test serum (0.2 mL). PEG (5%) did not augment cAMP produced by high TSH serum (127-210 mU/L) in thyroiditis chronica. sTSAb activity was negative in adenomatous goiter, subacute thyroiditis, and thyroid cancer. sTSAb activity was also negative in TSH stimulation blocking antibody (TSBAb)-positive hypothyroidism (during thyroxine [T4] treatment), but was positive in Graves' sera with coexistence serum of TSAb and TSBAb because of augmentative effect of 5% PEG on TSAb activity. This assay in whole serum (0.05 mL) containing 5% PEG is less sensitive than sensitive TSAb assay using PEG 22.5% PF from test serum (0.2 mL), but this method can be available clinically as routine TSAb assay using whole serum because of the technical simplicity.
此前我们报道,来自促甲状腺素抗体(TSAb)阳性血清的聚乙二醇(PEG)22.5%沉淀组分(PF)(粗免疫球蛋白G [IgG])产生的环磷酸腺苷(cAMP)量高于PEG 12.5% PF产生的量,并且在猪甲状腺细胞(PTC)试验中,PEG(5%)增强了亲和纯化的TSAb-IgG刺激的cAMP产生。在本研究中,我们在PTC试验中使用高浓度PEG的情况下,研究了使用全血清的敏感TSAb检测方法。TSAb阳性血清产生的cAMP与血清量成正比增加,直至0.05 mL,但在0.075 mL时逐渐减少。在5% PEG(终浓度)中发现PEG对TSAb阳性血清(0.05 mL)刺激的cAMP产生具有最大增强作用。因此,进行了在无5% PEG情况下使用全血清(0.05 mL)的TSAb检测(血清法)和在有5% PEG情况下使用全血清(0.05 mL)的敏感TSAb(sTSAb)检测(血清加5% PEG法)。格雷夫斯病血清的敏感促甲状腺素抗体(sTSAb)活性与血清的简单TSAb活性相比显著更高(两倍至七倍)。未经治疗的甲状腺功能亢进格雷夫斯病患者中,sTSAb和TSAb活性在91%(29/32)和47%(15/32)的患者中呈阳性。在许多格雷夫斯病血清中,血清加5% PEG法的sTSAb活性高于来自检测血清(0.2 mL)的PEG 12.5%沉淀组分(PF)的活性,但低于来自检测血清(0.2 mL)的PEG 22.5% PF的活性。PEG(5%)在慢性甲状腺炎中未增强高促甲状腺素(TSH)血清(127 - 210 mU/L)产生的cAMP。腺瘤性甲状腺肿、亚急性甲状腺炎和甲状腺癌中的sTSAb活性为阴性。TSH刺激阻断抗体(TSBAb)阳性的甲状腺功能减退症(甲状腺素 [T4] 治疗期间)中的sTSAb活性也为阴性,但在同时存在TSAb和TSBAb血清的格雷夫斯病血清中为阳性,因为5% PEG对TSAb活性有增强作用。这种在含5% PEG的全血清(0.05 mL)中的检测方法不如使用来自检测血清(0.2 mL)的PEG 22.5% PF的敏感TSAb检测方法敏感,但由于技术简单,该方法可作为使用全血清的常规TSAb检测方法在临床上应用。